Critics say U.K. decision on ALS drug could have ‘chilling effect' on access to new genetic medicines

Neurologists and patient advocates are up in arms over a policy decision by a U.K. health agency that they say will imperil access to an ALS treatment that's available in the U.S. and on its way to approval in the European Union.

You are viewing a robot-friendly page.Click hereto reload in standard format.